---
title: "Lake Street Keeps Their Buy Rating on inTEST (INTT)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285217356.md"
description: "Lake Street analyst Frank Takkinen has maintained a Buy rating on inTEST (INTT) with a price target of $19.00. Takkinen, who has an average return of -0.6% and a 38.90% success rate, focuses on the Healthcare sector. The analyst consensus for inTEST is a Moderate Buy, with a price target consensus of $16.50."
datetime: "2026-05-05T13:16:17.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285217356.md)
  - [en](https://longbridge.com/en/news/285217356.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285217356.md)
---

# Lake Street Keeps Their Buy Rating on inTEST (INTT)

Lake Street analyst Frank Takkinen reiterated a Buy rating on inTEST today and set a price target of $19.00.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

According to TipRanks, Takkinen is an analyst with an average return of \-0.6% and a 38.90% success rate. Takkinen covers the Healthcare sector, focusing on stocks such as Daxor, Stereotaxis, and CVRx.

inTEST has an analyst consensus of Moderate Buy, with a price target consensus of $16.50.

### Related Stocks

- [INTT.US](https://longbridge.com/en/quote/INTT.US.md)
- [DXR.US](https://longbridge.com/en/quote/DXR.US.md)
- [STXS.US](https://longbridge.com/en/quote/STXS.US.md)
- [CVRX.US](https://longbridge.com/en/quote/CVRX.US.md)

## Related News & Research

- [A Look At InTest (INTT) Valuation After Earnings Beat And Raised Revenue Guidance](https://longbridge.com/en/news/286600868.md)
- [inTEST Q1 revenue rises 27%, adjusted EPS beats estimates](https://longbridge.com/en/news/285186379.md)
- [LifeSci Capital Sticks to Their Buy Rating for MoonLake Immunotherapeutics (MLTX)](https://longbridge.com/en/news/286649191.md)
- [LifeSci Capital Sticks to Its Buy Rating for Neurogene (NGNE)](https://longbridge.com/en/news/286648209.md)
- [Damora Therapeutics (DMRA) Receives a Rating Update from a Top Analyst](https://longbridge.com/en/news/286678740.md)